Onishi T, Ohishi Y, Iizuka N, Suzuki Y, Hatano T, Makino H, Tomita M
Department of Urology, Jikei University School of Medicine, Japan.
Nihon Hinyokika Gakkai Zasshi. 1996 Mar;87(3):660-6. doi: 10.5980/jpnjurol1989.87.660.
We tried to identify which size or less means small size in renal cell carcinoma (RCC) associated with prognosis including Robson's stage 1.
We classified RCC based upon the tumour size into cases with 2.5 cm or less (NO, VO, MO: group I: n = 27, cause-specific cases = 26) and cases with 2.6 to 3.0 cm (NO, VO, MO: group II: n = 31, cause-specific cases = 27). Based upon this classification, we studied on the clinical features of small size RCC.
(1) Regarding the clinical features including mean age, sex ratio, affected side, opportunity of diagnosis, diagnostic approach and preoperative laboratory findings, no specific difference was observed between groups I and II except for the localization of tumour in the kidney (a significantly high rate was observed in the mid portion of the tumour in group I compared with that in group II). 2) The mean size of group I was 1.98 cm (0.7 to 2.5 cm), and that of group II was 2.84 cm (2.6 to 3.0 cm). On the other hand, the mean size of Robson's stage 1 was 5.5 cm (0.7 to 18.0 cm). Therefore, the tumour size of Robson's stage 1 was significantly larger than that of groups I and II (p < 0.001). 3) The survival rate of group I showed worse trend than that of group II after 12 years postoperatively, but no significant difference was observed between these 2 groups. Furthermore, the survival rate of Robson's stage 1 showed better trend than that of the tumour size with 3.0 cm or less, but no significant difference was observed between these 2 groups. 4) As to the grade in each group, no significant difference of survival was observed. 5) As to the recurrent rate in each group, it was 19.2% in group I, 7.4% in group II and 18.5% in Robson's stage 1. Therefore, no significant difference of recurrent rate was observed in these groups.
It is difficult to identify which size or less means small size RCC associated with prognosis. This is because no specific clinical feature was observed in these small size cases compared with Robson's stage 1 which consisted with larger size tumour.
我们试图确定在包括罗布森分期1期在内的与预后相关的肾细胞癌（RCC）中，多大尺寸及以下意味着小尺寸。
我们根据肿瘤大小将RCC分为肿瘤大小在2.5 cm及以下的病例（NO、VO、MO：I组：n = 27，特定病因病例 = 26）和肿瘤大小在2.6至3.0 cm的病例（NO、VO、MO：II组：n = 31，特定病因病例 = 27）。基于此分类，我们研究了小尺寸RCC的临床特征。
（1）关于包括平均年龄、性别比、患侧、诊断时机、诊断方法和术前实验室检查结果等临床特征，I组和II组之间未观察到特定差异，但肿瘤在肾脏内的定位除外（与II组相比，I组肿瘤中部的发生率显著更高）。（2）I组的平均大小为1.98 cm（0.7至2.5 cm），II组的平均大小为2.84 cm（2.6至3.0 cm）。另一方面，罗布森分期1期的平均大小为5.5 cm（0.7至18.0 cm）。因此，罗布森分期1期的肿瘤大小显著大于I组和II组（p < 0.001）。（3）术后12年，I组的生存率显示出比II组更差的趋势，但这两组之间未观察到显著差异。此外，罗布森分期1期的生存率显示出比肿瘤大小在3.0 cm及以下的情况更好的趋势，但这两组之间未观察到显著差异。（4）至于每组的分级，生存率未观察到显著差异。（5）至于每组的复发率，I组为19.2%，II组为7.4%，罗布森分期1期为18.5%。因此，这些组之间的复发率未观察到显著差异。
很难确定多大尺寸及以下意味着与预后相关的小尺寸RCC。这是因为与由较大尺寸肿瘤组成的罗布森分期1期相比，这些小尺寸病例未观察到特定的临床特征。
